BRD4 and neoplasm: engineered a radiosensitizer by integrating the CRGDK peptide, which recognizes the target NRP‐1 to effectively deliver proteolysis‐targeting chimera prodrugs.[136] This prodrug downregulates the BRD4‐RAD51AP1 pathway, providing a potential platform for tumor‐specific radiosensitization.